PCM
ARQT icon

Penserra Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Penserra Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-82,463
Closed -$2.39M – 1087
2025
Q4 		$2.39M Buy
+82,463
New +$2.11M 0.03% 326
2025
Q2 		– Sell
-118,521
Closed -$1.85M – 1027
2025
Q1 		$1.85M Buy
+118,521
New +$1.67M 0.03% 315
2021
Q4 		– Sell
-1,155
Closed -$27K – 1372
2021
Q3 		$27K Buy
1,155
+10
+0.9% +$228 ﹤0.01% 1201
2021
Q2 		$31K Buy
1,145
+15
+1% +$423 ﹤0.01% 1088
2021
Q1 		$32K Buy
1,130
+130
+13% +$4.06K ﹤0.01% 886
2020
Q4 		$28K Buy
+1,000
New +$24.5K ﹤0.01% 792

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return